[A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists].
「胰高血糖素樣肽-1 受體激動劑到共激動劑和多重激動劑:胰島素增效劑的新時代」
Rev Med Liege 2024-09-12
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
GLP-1/GIP 受體共激動劑用於心臟保護、2型糖尿病和肥胖:機制和臨床數據綜述。
Curr Opin Cardiol 2023-11-02
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.
胰高血糖素類多肽激素作用的藥物學進展:我們所知道的與我們不知道的。
Physiology (Bethesda) 2024-03-29
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
腸道激素多激動劑用於治療第2型糖尿病和肥胖:進展與挑戰。
J Endocrinol 2024-06-25